Data/trials18 Apr 2026 19:32
I read through the various RNS's re data and trials. And went back over the RPDD and Orphan Drug designation RNS's. But...are some people concerned that with MCW sponsoring the trial that MCW have a financial stake in the results of the trial? And to be honest I don't know what the kind of commercial or contractual arrangement IBAI have with MCW.
But how do you factor in this trial - below - which is another gallium trial sponsored by MCW....
Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma
ClinicalTrials.gov ID NCT04319276
Sponsor Medical College of Wisconsin
Information provided by Jennifer Connelly, MD, Medical College of Wisconsin (Responsible Party)
Last Update Posted 2025-11-03
that makes 2 trials sponsored by MCW - including this older one? for me its all 2 confusing to lose any sleep over. perhaps because I always guessed (it was only a guess) that the gallium project's value was in the benefit to patients and then improved kudos and status as it would raise the profile of the company and its team. But writing as someone who doesn't work in pharma or the pharma/finance sector I can honestly share no certainty about any of this - and I am ok with that. This is not my field so I don't feel that I can easily understand the moves and their meaning. When I do have a question or a concern I will email the company.